A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
07/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +45 locations
Conditions: Early Alzheimer's Disease
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620
Recruiting
The investigators will compare PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Perelman Center for Advance Medicine, Philadelphia, Pennsylvania
Conditions: Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Recruiting
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California +265 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Recruiting
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Myeloma
NASH AMPK Exercise Dosing (AMPED) Trial
Recruiting
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
07/31/2025
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: NAFLD
US Post-Market Surveillance Study of the Surfacer System
Recruiting
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Pima Heart and Vascular, Tucson, Arizona +5 locations
Conditions: Venous Disease
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Recruiting
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective: To test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment. Eligibility: People ages 18 and older with newly diagnosed prostate cancer who have no evidence of distant metastatic disease and plan to get stereotactic body radiation ther... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Localized Prostate Cancer
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Recruiting
Background: People with sickle cell disease (SCD) have problems with their heart, brain, kidneys, liver, and lungs as they age. These problems may improve after transplant. Researchers want to learn how and why this happens. Objective: To study the benefits of treatments that are intended to cure SCD. Eligibility: People aged 18 and older with SCD who are either receiving curative therapy in the next 3 months or don t have any plans to receive a curative therapy in the next 2 years. Design... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mortality in Sickle Cell, Sickle Cell Cardiopulmonary Complications, Sickle Cell Organ Damage, Sickle Cell Life Expectancy and Risk Factors for Early Death, Sickle Cell Lung Disease and Sudden Death
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
Recruiting
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/31/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Non-Small Cell Lung Cancer
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
Recruiting
The purpose of this study is to compare the efficacy and safety of a real time video telehealth pulmonary rehabilitation intervention with standard of care in patients hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD) to determine the impact on hospital readmissions and respiratory morbidity, and to investigate the cost-effectiveness of the intervention.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +14 locations
Conditions: Chronic Obstructive Pulmonary Disease
Multi-System Analysis of Opioid Receptor Binding
Recruiting
This study will enroll up to 60 adults (including 30 females and 30 males) in three cohorts of up to 20 subjects each. In all three groups, \[11C\]carfentanil whole-body PET imaging will be used to examine the central nervous system (CNS) and broader systemic opioid binding in an initial scan session. In the two groups not receiving standard of care medication assisted treatment (MAT) for opioid use disorder (OUD) the effects on \[11C\]carfentanil binding potential of the blockade of opioid bind... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/31/2025
Locations: University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Healthy, Opioid Use Disorder
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
Recruiting
Background: Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS. Researchers want to learn more through this natural history study so they can develop better treatments. Objective: To study the natural course of MDS and MDS/myeloproliferative neoplasms (MPN) and collect biological samples that can help researchers understand the disease. Eligibility: People with suspected or confirmed MDS or MDS/MPN. Healthy do... Read More
Gender:
ALL
Ages:
Between 1 day and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myelodysplastic Syndromes